Piramal Enterprises has received an approval for issue of secured Non-Convertible Debentures (NCDs) up to Rs 600 crore with an option to retain over-subscription of Rs 500 crore, aggregating the total issue size to Rs 1,100 crore on private placement basis. These NCDs are proposed to be listed on Wholesale Debt Market segment of NSE. The Administrative Committee constituted by the Board of Directors of the Company at its meeting held on June 20, 2017 has approved for the same.
Piramal Enterprises is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.
